Ecommerce Trends: Who Are the Top Online Retailers in Health & Beauty?

Why It Matters

The breakthrough underscores how digitally native health brands can outpace legacy retailers and reshape pharma distribution, signaling a shift in the Health & Beauty e‑commerce landscape.

Key Takeaways

• $2.35B 2025 sales, #5 health & beauty
• 63% YoY ecommerce growth in 2025
• Ranked #68 among all North American retailers
• Resolved lawsuit, now sells Ozempic and Wegovy
• Partnership expands GLP‑1 offerings, boosting revenue

Pulse Analysis

Hims & Hers’ rapid ascent reflects a broader transformation in health‑focused e‑commerce, where subscription‑based platforms leverage data‑driven marketing to capture consumer spend traditionally held by brick‑and‑mortar chains. By delivering telehealth services alongside over‑the‑counter products, the company tapped unmet demand for convenient, discreet care, driving a compound annual growth rate that eclipsed industry averages. Its inclusion in Digital Commerce 360’s Top 2000 not only validates the model but also highlights the scalability of digital health marketplaces in a post‑pandemic economy.

The health and beauty sector is increasingly fragmented, with legacy players like Walgreens and Ulta battling agile newcomers for digital share. Hims & Hers differentiated itself through a focused product mix—personal care, sexual health, and now GLP‑1 weight‑loss drugs—paired with a seamless checkout experience. The 63% sales surge in 2025 was fueled by aggressive acquisition of high‑margin SKUs and strategic SEO investments that captured intent‑rich traffic. This growth trajectory forces incumbents to accelerate their own digital transformations or risk losing relevance among younger, tech‑savvy shoppers.

The resolution of the Novo Nordisk lawsuit marks a pivotal moment for pharma‑e‑commerce collaborations. By securing rights to sell branded GLP‑1 therapies such as Ozempic and Wegovy, Hims & Hers can monetize a high‑ticket, prescription‑driven category while offering patients a streamlined ordering process. This partnership may set a precedent for other drug manufacturers seeking direct‑to‑consumer channels, potentially reshaping regulatory frameworks and distribution economics. Investors will watch closely as the company leverages this expanded portfolio to sustain its growth momentum into 2026 and beyond.